efficacy of conbercept combined dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046387

Enrollment

Unknown

Registered

2021-05-15

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion

Interventions

Experimental group:Joint injection

Control group:Anti-VEGF therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with macular edema secondary to RVO; 2. The central foveal thickness (CFT)> 300 µm and the best-corrected visual acuity (BCVA) is less than or equal to 20/40; 3. Aged 18 to 80 years.

Exclusion criteria

Exclusion criteria: Patients with iris reddening, late glaucoma (defined as cup-to-disk ratio> 0.8), or history of vitrectomy, cataract surgery, and retinal photocoagulation.

Design outcomes

Primary

Measure	Time frame
retreatment time;visual acuity;central foveal thickness;superficial vessel density;density vessel density;	—

Countries

China

Contacts

Public ContactJiao Mingfei

Tianjin Medical University Eye Hospital

jiaomingfei2004@163.com+86 22 86428729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026